Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q96RG2
UPID:
PASK_HUMAN
Alternative names:
-
Alternative UPACC:
Q96RG2; G5E9F1; Q05BE4; Q68DY3; Q6GSJ5; Q86XH6; Q99763; Q9UFR7
Background:
The PAS domain-containing serine/threonine-protein kinase plays a pivotal role in energy homeostasis and protein translation. It is known for phosphorylating key proteins such as EEF1A1, GYS1, PDX1, and RPS6, adapting to environmental changes like oxygen, glucose, and nutrition levels. Its involvement in glycogen synthesis regulation, insulin production, and protein translation efficiency highlights its critical function in cellular metabolism and respiratory regulation.
Therapeutic significance:
Understanding the role of PAS domain-containing serine/threonine-protein kinase could open doors to potential therapeutic strategies.